Latest news
BMY Looks 14.7% Overvalued on GF Value™ as Dividend Sustainabili - GuruFocusGuruFocus · Sat, 08 Aug 2026 21:26:11 GMTBristol-Myers Squibb Co (BMY) Stock Down 3.4% but Still Overvalued -- GF Score: 71/100 - GuruFocusGuruFocus · Wed, 05 Aug 2026 21:35:11 GMTBMY Upgraded by Argus Research -- Rating Changed to Buy - GuruFocusGuruFocus · Wed, 05 Aug 2026 16:03:40 GMTBMY Looks 17.0% Overvalued on GF Value™ as Dividend Sustainabili - GuruFocusGuruFocus · Wed, 05 Aug 2026 15:02:10 GMTBMY Maintained by Citigroup -- Price Target Raised to $70 - GuruFocusGuruFocus · Tue, 04 Aug 2026 10:52:30 GMTPotential Merger Between Bristol-Myers Squibb (BMY) and AstraZen - GuruFocusGuruFocus · Mon, 03 Aug 2026 18:00:00 GMTBMY Looks 16.5% Overvalued on GF Value™ as Dividend Sustainabili - GuruFocusGuruFocus · Sun, 02 Aug 2026 16:18:45 GMTBMY Looks 18.8% Overvalued on GF Value™ as Dividend Appeal Stren - GuruFocusGuruFocus · Fri, 31 Jul 2026 20:11:12 GMT